Rubrik: Biotechnologie
(Treffer aus pharmind, Nr. 02, Seite 281 (2018))
Lütke-Eversloh T | Rogge P
Biopharmaceutical Manufacturing in Single-Use Bioreactors / Current Status and Challenges from a CDMO Perspective · Lütke-Eversloh T, Rogge P · Rentschler Biopharma SE, Laupheim
The manufacturing of biopharmaceuticals constitutes a fast growing market segment, and many therapeutic proteins are currently in clinical trials and more sophisticated molecules for specialized therapies are developed. These include monoclonal antibodies (mAb), enzymes, hormones, fusion proteins and other recombinant proteins, which are used for the treatment of severe diseases, particularly cancer, autoimmune and genetic disorders. Typically, modern biopharmaceuticals exhibit improved potency and pharmacokinetic properties, and thus, can be applied in significantly lower doses. Since many companies outsource the process development and material supply for clinical studies, the field of Contract Development and Manufacturing Organizations (CDMOs) is growing as well ...